News

The acquisition of this product will help the company focus beyond addiction and pain to include schizophrenia and other serious psychiatric disorders. With the acquisition of risperidone, Braeburn

Tuzistra XR is an extended-release oral suspension combination of codeine and chlorpheniramine indicated for oral use for relief of cough and symptoms associated with upper respiratory allergies or

Results from the multicenter, randomized, placebo controlled Phase III trial (MDS-005) showed that significantly more patients treated with lenalidomide achieved red-blood-cell-transfusion independence (RBC-TI) of at least 56 days

Under the deal, PeptiDream will use its peptide discovery platform system (PDPS) technology to produce macrocylic/constrained peptides against multiple targets of interest selected by Merck. Merck will have

"We have already seen good evidence that Luminate can induce PVD in patients with diabetic macular edema," says Baruch Kuppermann, M.D., Ph.D., Professor of Ophthalmology and Biomedical Engineering,

F-652 was demonstrated to be safe in a Phase I study conducted in Australia in healthy volunteers in 2013. In addition, F-652 showed good pharmacokinetic (PK) and biomarker

The Cranbury facility is designed to utilize multiple technologies that enable rapid deployment of flexible manufacturing at commercial scale. Through the use of the latest single-use technologies, the

Burixafor (TG-0054) is a new, potent and selective chemokine receptor antagonist discovered by TaiGen. Around 15 patients will be enrolled in this open-label trial, which is designed to

The research is part of the Semiconductor Synthetic Biology (SSB) program sponsored and managed by Semiconductor Research Corporation (SRC), the world’s leading university-research consortium for semiconductor technologies. Launched